Advertisement
About Celator
Celator Pharmaceuticals, Inc., is a privately held pharmaceutical companyworking to develop new and more effective therapies to treat cancer.CombiPlex(TM), the company's drug ratio technology platform, represents arevolutionary new approach to the development of combination therapies basedon identifying a fixed, synergistic ratio of the drugs pre-clinically,incorporating that ratio in a drug delivery vehicle and maintaining the ratioin patients. The company pipeline includes: CPX-1 (a liposomal formulation ofirinotecan:floxuridine), currently in a Phase 2 trial in patients withcolorectal cancer; CPX-351 (a liposomal formulation ofcytarabine:daunorubicin), currently in a Phase 1 trial in patients withleukemia; CPX 571 (a liposomal formulation of irinotecan:cisplatin), apreclinical stage compound; and multiple research programs. Based on theapplications of CombiPlex, Celator is positioned to advance a broad pipelineof combination therapies involving both previously approved and novel drugagents. For more information, please visit the company's website atwww.celatorpharma.com.
SOURCE Celator Pharmaceuticals